- Italfarmaco Group adds innovative Alzheimer’s disease therapy to its neurology-based product portfolio – MILAN & BASEL, Switzerland--(BUSINESS WIRE)--Italfarmaco Group (Italfarmaco) and Luye Pharma ...

March 30, 2011 (Toronto, Ontario) — Caregivers using a transdermal patch to administer cholinesterase inhibitor (ChEI)–based therapy in individuals with Alzheimer's disease (AD) report greater overall ...

BRIDGEWATER, N.J., Jan. 14, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received FDA approval for a generic version of Exelon ® Patch (Rivastigmine ...

Novartis Corporation's Exelon Patch Receives First Worldwide Approval in US EAST HANOVER, N.J., July 9 -- Exelon Patch (rivastigmine transdermal system) has received its first worldwide approval in ...

According to the World Health Organization (WHO), an estimated 50 million people are living with dementia globally. This number is projected to increase to 82 million by 2030 and over 150 million by ...

China’s National Medical Products Administration has approved Sino Biopharmaceutical Ltd.’s rivastigmine transdermal patch to treat mild to moderate Alzheimer’s disease. Developed by Sino Biopharm, ...

Luye Pharma Group today announced that its subsidiary Luye Pharma Switzerland AG has entered into agreements with Exeltis Pharma México, S.A. de C.V and Exeltis Pharmaceuticals Holding, S.L (Exeltis), ...

PINE BROOK, N.J.--(BUSINESS WIRE)--Today, Alvogen has launched the first generic equivalent of Exelon® patch (rivastigmine transdermal system) in the United States. The product will be marketed by ...

Breckenridge has received the Food and Drug Administration’s green light for rivastigmine transdermal system in dosage strengths of 4.6mg/24 hours, 9.5mg/24 hours and 13.3mg/24 hours. The product is ...

Transdermal therapeutic systems (TTSs) are commonly used to treat many diverse medical conditions. There are several advantages to this form of drug delivery; however, adverse cutaneous reactions are ...